Parkinson's disease, dopamine pathways, movement disorders, and neuroprotection
138 articles
A major review reveals how growth hormone and IGF-1 regulate cognition, mood, and neurodegeneration — with direct implications for aging brains.
A flexible 3D crystal framework selectively traps xenon over krypton using temperature and the gas itself as triggers.
New research reveals how lipid droplets spark the protein aggregation at the heart of Parkinson's disease, disrupting energy metabolism.
New review links physical activity to glymphatic function — the brain's built-in detox network that flushes neurotoxic proteins.
A newly identified TFEB-ATP6V0C axis in microglia controls alpha-synuclein clearance — and restoring it reduces Parkinson's pathology in mice.
A landmark Nature Immunology review reveals adaptive immune cells actively shape neurodegeneration — and could be targeted therapeutically.
A landmark review reveals astrocytes as active immune players whose dysfunction drives Alzheimer's, Parkinson's, MS, and ALS.
UCLA researchers found long-term chlorpyrifos exposure more than doubles Parkinson's risk and damages dopamine neurons directly.
A paradigm-shifting review proposes that α-synuclein pathology originates in the kidneys and spreads to the brain via PKC signaling.
Chronic colitis causes dopaminergic neuron loss in mice, but blocking a single immune receptor completely prevents it.
Completed French trial uses advanced brain imaging to track 5-HT4 serotonin receptors in Parkinson's patients, linking genetics to cognitive and mood changes.
An interpretable machine learning model using MRI brain texture features diagnosed and staged Parkinson's disease with up to 90% accuracy across multiple centers.
